Aberdeen Proving Ground, Edgewood, Md. –
On January 9, 2024, the U.S. Department of Defense (DOD) awarded an indefinite delivery/indefinite quantity (ID/IQ) procurement contract to Emergent BioSolutions, Inc. to supply the U.S. Food and Drug Administration (FDA)-approved BioThrax® (Anthrax Vaccine Adsorbed), a pre-exposure prophylaxis (PrEP) for anthrax disease, for use by all branches of service over the next ten years. Led by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, the new contract has a maximum value of up to $235.8 million, comprised of a five-year base contract ending on September 30, 2028, and an additional five-year option that could extend the contract to September 30, 2033.
“The JPEO-CBRND, on behalf of the DOD and with the Defense Health Agency, avoids gaps in warfighter protection and delivers critical biodefense capabilities as one team,” said COL Matthew Clark, Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical, a component of the JPEO-CBRND. “This award highlights our shared commitment to continue to provide a layered defense against threats like anthrax to the warfighter.”
Under the initial five-year ID/IQ contract, there is a guaranteed purchase minimum of $20.1 million, with future orders are currently estimated to be at least $20 million for each following year, for a total award value up to $235.8 million.
“Emergent is proud to continue supporting and preparing our Nation’s service members who have a high risk of exposure to anthrax bacteria by supplying BioThrax® vaccine,” said Paul Williams, senior vice president, products head at Emergent. “This contract award is a testament to the importance of our medical countermeasures portfolio, which continues to meet the needs of our military forces. We look forward to our long-standing collaboration with the JPEO-CBRND as we deliver on our commitments of this new contract award.”
The BioThrax® vaccine is indicated for the active immunization for the prevention of disease caused by Bacillus anthracis in persons 18 through 65 years of age, as well as for pre-exposure prophylaxis in persons at high risk of exposure. It is also approved for post-exposure prophylaxis of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with recommended antibacterial drugs.
### About the JPEO-CBRND:
The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) mission is to provide an integrated layered chemical, biological, radiological, and nuclear defense capabilities to the joint force across combined Joint All-Domain Operations. JPEO-CBRND’s goal is to enable the joint force to fight and win unencumbered by a CBRN environment. To learn more about JPEO-CBRND, visit: https://www.jpeocbrnd.osd.mil/, or follow JPEO-CBRND on social media @JPEOCBRND.About the JPM CBRN Medical:
The Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), a component of the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, aims to provide U.S. military forces and the nation with safe, effective, and innovative medical solutions to counter chemical, biological, radiological, and nuclear threats. The JPM CBRN Medical facilitates the advanced development and acquisition of medical countermeasures and systems to enhance the nation’s biodefense response capability.